Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A protocol for an international, multicentre pharmacokinetic study for Screening Antifungal Exposure in Intensive Care Units: The SAFE-ICU study.
Roberts JA, Sime F, Lipman J, Hernández-Mitre MP, Baptista JP, Brüggemann RJ, Darvall J, De Waele JJ, Dimopoulos G, Lefrant JY, Mat Nor MB, Rello J, Seoane L, Slavin MA, Valkonen M, Venditti M, Wong WT, Zeitlinger M, Roger C. Roberts JA, et al. Among authors: slavin ma. Crit Care Resusc. 2023 May 20;25(1):1-5. doi: 10.1016/j.ccrj.2023.04.002. eCollection 2023 Mar. Crit Care Resusc. 2023. PMID: 37876989 Free PMC article.
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR 3rd, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, Poromanski I, Dignani C, Das AF, Sandison T, Pappas PG; ReSTORE trial investigators. Thompson GR 3rd, et al. Lancet. 2023 Jan 7;401(10370):49-59. doi: 10.1016/S0140-6736(22)02324-8. Epub 2022 Nov 25. Lancet. 2023. PMID: 36442484 Free article. Clinical Trial.
International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship.
Raad II, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Fernández Cruz A, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S, Dragovich T, Vong Kiat YE, Fakhreddine S, Pierre AH, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Yepez EY, Torres HA, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, García AG, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA; Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team; Kontoyiannis DP, Malek AE, Chaftari AM. Raad II, et al. Elife. 2023 Jan 30;12:e81127. doi: 10.7554/eLife.81127. Elife. 2023. PMID: 36715684 Free PMC article.
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients.
Teh BW, Mikulska M, Averbuch D, de la Camara R, Hirsch HH, Akova M, Ostrosky-Zeichner L, Baddley JW, Tan BH, Mularoni A, Subramanian AK, La Hoz RM, Marinelli T, Boan P, Aguado JM, Grossi PA, Maertens J, Mueller NJ, Slavin MA. Teh BW, et al. Among authors: slavin ma. Lancet Infect Dis. 2024 Jan;24(1):e59-e68. doi: 10.1016/S1473-3099(23)00377-8. Epub 2023 Sep 6. Lancet Infect Dis. 2024. PMID: 37683684 Review.
Management of COVID-19 in Immunocompromised Patients: An ESCMID Consensus Document.
Bartoletti M, Azap O, Barac A, Ben Selma M, Ergonul O, Gkrania-Klotsas E, Grossi PA, Krause R, Nagavci B, Paño-Pardo JR, Pierrotti LC, Power N, Rodríguez-Baño J, Sibani M, Slavin MA, Szabo BG, Tazza B, Yung Tsang NN, Tsiodras S, Zollner-Schwetz I, Chemaly RF; ESCMID Study Group for Infections in Compromised Hosts and the ESCMID Study Group for Respiratory Viruses. Bartoletti M, et al. Among authors: slavin ma. Clin Microbiol Infect. 2025 Jun 23:S1198-743X(25)00281-2. doi: 10.1016/j.cmi.2025.05.032. Online ahead of print. Clin Microbiol Infect. 2025. PMID: 40562174
Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.
Maertens JA, Thompson GR 3rd, Spec A, Donovan FM, Hammond SP, Bruns AHW, Rahav G, Shoham S, Johnson R, Rijnders B, Schaenman J, Hoenigl M, Morrissey CO, Mehta SR, Heath CH, Koehler P, Paterson DL, Slavin MA, Fortún J, Nguyen MH, Patterson TF, Uspenskaya O, Van de Veerdonk FL, Verweij PE, Aoun M, Georgala A, Alexander BD, Chayakulkeeree M, Mehra V, Miceli MH, Sikka MK, Solé A, Walsh TJ, Aguado JM, Holland SM, Moussa M, Rautemaa-Richardson R, Bazaz R, Schwartz S, Walsh SR, Plate M, Yehudai-Ofir D, Brüggemann RJ, Cornely OA, Ostrosky-Zeichner L, Vazquez JA, White PL, Cornelissen K, Ross GG, Fitton L, Dane A, Zinzi D, Rex JH, Chen SC. Maertens JA, et al. Among authors: slavin ma. Lancet Infect Dis. 2025 Jun 17:S1473-3099(25)00224-5. doi: 10.1016/S1473-3099(25)00224-5. Online ahead of print. Lancet Infect Dis. 2025. PMID: 40541222
335 results